CorMedix to acquire Heron Therapeutics assets, reports Q3 2026 resultsNov 12Quarterly updateCorMedix Inc.
CorMedix to acquire nearly all of Heron Therapeutics' assets in cash-and-stock dealNov 9M&ACorMedix Inc.Heron Therapeutics, Inc. /De/Updated
CorMedix reaffirms 2026 revenue guidance, details 2027 DefenCath payment outlookNov 2Quarterly updateCorMedix Inc.taurolidine and heparin
CorMedix reports Q2 2026 results, flags REZZAYO filing and DefenCath supply dealAug 13Quarterly updateCorMedix Inc.rezafungin